Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2016397
Abstract: ABSTRACT Introduction Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody that is the first targeted therapy to be approved for non-small cell lung cancer (NSCLC) patients harboring EGFR exon 20 insertion mutations following progression on chemotherapy,… read more here.
Keywords: exon insertion; egfr exon; small cell; non small ... See more keywords